Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

449 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Accuracy of free-breathing multi-parametric SASHA in identifying T1 and T2 elevations in pediatric orthotopic heart transplant patients.
Richmann DP, Contento J, Cleveland V, Hamman K, Downing T, Kanter J, Berger JT 3rd, Christopher A, Cross R, Chow K, Olivieri L. Richmann DP, et al. Among authors: kanter j. Int J Cardiovasc Imaging. 2024 Jan;40(1):83-91. doi: 10.1007/s10554-023-02965-0. Epub 2023 Oct 24. Int J Cardiovasc Imaging. 2024. PMID: 37874446 Free PMC article.
A phantom for targeted endomyocardial biopsy training.
Contento J, Cleveland V, Ehtiati T, Olivieri L, Kanter J. Contento J, et al. Among authors: kanter j. Catheter Cardiovasc Interv. 2023 Nov;102(6):1109-1113. doi: 10.1002/ccd.30862. Epub 2023 Oct 19. Catheter Cardiovasc Interv. 2023. PMID: 37855199
Costs and Impact of Disease in Adults with Sickle Cell Disease: A Pilot Study.
Lanzkron S, Crook N, Wu J, Hussain S, Curtis R, Robertson D, Baker JR, Nugent D, Soni A, Roberts JC, Ullman M Ms, Kanter J, Nichol M. Lanzkron S, et al. Among authors: kanter j. Blood Adv. 2024 May 22:bloodadvances.2023012477. doi: 10.1182/bloodadvances.2023012477. Online ahead of print. Blood Adv. 2024. PMID: 38776399
Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.
Kanter J, Ataga KI, Bhasin N, Guarino S, Kutlar A, Lanzkron S, Manwani D, McGann P, Stowell SR, Tubman VN, Yermilov I, Campos C, Broder MS. Kanter J, et al. Ann Hematol. 2024 Jun;103(6):1909-1917. doi: 10.1007/s00277-024-05736-6. Epub 2024 Apr 20. Ann Hematol. 2024. PMID: 38642304 Review.
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial.
Gladwin MT, Gordeuk VR, Desai PC, Minniti C, Novelli EM, Morris CR, Ataga KI, De Castro L, Curtis SA, El Rassi F, Ford HJ, Harrington T, Klings ES, Lanzkron S, Liles D, Little J, Nero A, Smith W, Taylor JG 6th, Baptiste A, Hagar W, Kanter J, Kinzie A, Martin T, Rafique A, Telen MJ, Lalama CM, Kato GJ, Abebe KZ. Gladwin MT, et al. Among authors: kanter j. Lancet Haematol. 2024 May;11(5):e345-e357. doi: 10.1016/S2352-3026(24)00045-0. Epub 2024 Mar 27. Lancet Haematol. 2024. PMID: 38554715 Clinical Trial.
449 results